Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Cash & Equivalents (2016 - 2025)

Haemonetics has reported Cash & Equivalents over the past 17 years, most recently at $363.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 13.25% year-over-year to $363.4 million; the TTM value through Dec 2025 reached $363.4 million, up 13.25%, while the annual FY2025 figure was $306.8 million, 71.57% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $363.4 million at Haemonetics, up from $296.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $363.4 million in Q4 2025 and troughed at $173.5 million in Q3 2021.
  • A 5-year average of $262.6 million and a median of $272.0 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 37.15% in 2024 and later skyrocketed 71.57% in 2025.
  • Year by year, Cash & Equivalents stood at $192.4 million in 2021, then rose by 16.41% to $224.0 million in 2022, then fell by 13.4% to $194.0 million in 2023, then soared by 65.4% to $320.8 million in 2024, then increased by 13.25% to $363.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for HAE at $363.4 million in Q4 2025, $296.4 million in Q3 2025, and $292.9 million in Q2 2025.